DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TREATMENTS
       *****************************************************
       #Post#: 3257--------------------------------------------------
       Fenebrutinib in the pipeline from Genentech
       By: agate Date: April 15, 2021, 12:42 am
       ---------------------------------------------------------
       The upcoming AAN conference will include presentations by
       Genentech, according to this April 7 press release from
       Genentech, which contains this about a new MS drug,
       fenebrutinib:
       [quote][font=Gene-Serif-Regular]Genentech is continuing to
       advance the science in MS and is exploring the investigational
       medicine fenebrutinib. Data from fenebrutinib, a highly
       selective, non-covalent, reversible oral BTKi, support its
       safety profile in several autoimmune diseases and high potency,
       which is encouraging for the ongoing Phase III studies in RMS
       and PPMS. Fenebrutinib is a dual inhibitor of both B-cell and
       myeloid lineage-cell activation, which may offer a novel
       approach to slowing disease progression by targeting both acute
       and chronic inflammatory aspects of MS.[/font][/quote]
       [font=verdana]BTKi = Bruton Tyrosine Kinase Inhibitor[/font]
       [font=verdana]The entire article:[/font]
  HTML https://www.gene.com/media/press-releases/14903/2021-04-07/new-genentech-data-at-2021-aan-highlight
       *****************************************************